...
【24h】

Incorporation of map kinases into the platelet cytoskeleton.

机译:将图激酶掺入血小板细胞骨架中。

获取原文
获取原文并翻译 | 示例

摘要

Erk1 (p44) and erk2 (p42) mitogen-activated protein (MAP) kinases are activated in agonist-stimulated platelets, although their role(s) in the activation process is unknown. In the present study, erk1, erk2 and the phosphorylated forms of both enzymes became associated with the contractile cytoskeleton in thrombin-stimulated platelets. Enzyme incorporation was accompanied by an increase in MAP kinase activity in the cytoskeleton, which was inhibited by PD98059. Pretreatment of the platelets with the arginine-glycine-aspartic acid-serine (RGDS) polypeptide enhanced both the cytoskeletal association and the enzyme activity, but cytochalasin D had no significant effect. Platelets from a patient with Glanzmann's thrombasthenia lack the alpha(IIb)beta(3) integrin and form only a rudimentary cytoskeleton, however, this cytoskeleton is enriched with both erk1 and erk2. These data suggest either that MAP kinases play a role in cytoskeletal rearrangement or that the cytoskeleton act as a frame to align MAP kinases with substrates in a highly integrated signal transduction pathway.
机译:Erk1(p44)和erk2(p42)促分裂原激活蛋白(MAP)激酶在激动剂刺激的血小板中被激活,尽管它们在激活过程中的作用尚不清楚。在本研究中,两种酶的erk1,erk2和磷酸化形式都与凝血酶刺激的血小板中的收缩细胞骨架有关。酶的掺入伴随着细胞骨架中MAP激酶活性的增加,这被PD98059抑制。用精氨酸-甘氨酸-天冬氨酸-丝氨酸(RGDS)多肽预处理血小板可以增强细胞骨架结合和酶活性,但细胞松弛素D没有明显作用。患有Glanzmann血栓性衰弱患者的血小板缺乏alpha(IIb)beta(3)整合素,仅形成基本的细胞骨架,但是,该细胞骨架同时富含erk1和erk2。这些数据表明,MAP激酶在细胞骨架重排中发挥作用,或者细胞骨架充当将MAP激酶与高度整合的信号转导途径中的底物对齐的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号